Last reviewed · How we verify
MBM-02
MBM-02 is a small molecule that targets the PI3K/AKT pathway.
MBM-02 is a small molecule that targets the PI3K/AKT pathway. Used for Metastatic non-small cell lung cancer, Metastatic breast cancer.
At a glance
| Generic name | MBM-02 |
|---|---|
| Also known as | Tempol; 4-hydroxy-tempo; 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl |
| Sponsor | Matrix Biomed, Inc. |
| Drug class | PI3K inhibitor |
| Target | PI3K |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
MBM-02 works by inhibiting the PI3K/AKT pathway, which is involved in cell proliferation and survival. This inhibition leads to the reduction of tumor growth and metastasis. MBM-02 has shown promise in preclinical studies for its potential to treat various types of cancer.
Approved indications
- Metastatic non-small cell lung cancer
- Metastatic breast cancer
Common side effects
- Diarrhea
- Nausea
- Fatigue
Key clinical trials
- Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients. (PHASE2, PHASE3)
- Treatment of Metastatic Cancer in Terminally Diagnosed Patients
- Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer (PHASE1)
- MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer (PHASE2)
- MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM) (PHASE2)
- A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MBM-02 CI brief — competitive landscape report
- MBM-02 updates RSS · CI watch RSS
- Matrix Biomed, Inc. portfolio CI